File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/COH.0000000000000652
- Scopus: eid_2-s2.0-85092514340
- PMID: 33002954
- WOS: WOS:000587785800003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Treatment of coronavirus disease 2019
Title | Treatment of coronavirus disease 2019 |
---|---|
Authors | |
Keywords | antivirals coronavirus disease 2019 severe acute respiratory syndrome coronavirus 2 treatment |
Issue Date | 2020 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.co-hivandaids.com/ |
Citation | Current Opinion in HIV and AIDS, 2020, v. 15 n. 6, p. 336-340 How to Cite? |
Abstract | Purpose of review:
Coronavirus disease 2019 (COVID-19) is a highly contagious and potentially lethal pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No specific antiviral treatment is currently available. The purpose of this review is to highlight the main repurposed drug treatments with in-vitro or in-vivo efficacy against the SARS-CoV-2.
Recent findings:
Recent clinical trials suggested remdesivir, IFN-β-1b and favipiravir have potential clinical and/or virological benefits on patients with COVID-19. Short course of stress dose of corticosteroids might be used as adjunctive treatment to patients who are late presenters with cytokine storm. Convalescent plasma from recovered COVID-19 patients with high neutralizing antibody might also be beneficial in the treatment of severe disease.
Summary:
Early effective antiviral therapy in COVID-19 patients will suppress the SARS-CoV-2 viral load. Adjunctive therapy with corticosteroid and convalescent plasma might further ameliorate the cytokine response. Further randomized clinical trials of combination therapy are needed. |
Persistent Identifier | http://hdl.handle.net/10722/289389 |
ISSN | 2021 Impact Factor: 4.061 2020 SCImago Journal Rankings: 1.901 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hung, IFN | - |
dc.date.accessioned | 2020-10-22T08:11:57Z | - |
dc.date.available | 2020-10-22T08:11:57Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Current Opinion in HIV and AIDS, 2020, v. 15 n. 6, p. 336-340 | - |
dc.identifier.issn | 1746-630X | - |
dc.identifier.uri | http://hdl.handle.net/10722/289389 | - |
dc.description.abstract | Purpose of review: Coronavirus disease 2019 (COVID-19) is a highly contagious and potentially lethal pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No specific antiviral treatment is currently available. The purpose of this review is to highlight the main repurposed drug treatments with in-vitro or in-vivo efficacy against the SARS-CoV-2. Recent findings: Recent clinical trials suggested remdesivir, IFN-β-1b and favipiravir have potential clinical and/or virological benefits on patients with COVID-19. Short course of stress dose of corticosteroids might be used as adjunctive treatment to patients who are late presenters with cytokine storm. Convalescent plasma from recovered COVID-19 patients with high neutralizing antibody might also be beneficial in the treatment of severe disease. Summary: Early effective antiviral therapy in COVID-19 patients will suppress the SARS-CoV-2 viral load. Adjunctive therapy with corticosteroid and convalescent plasma might further ameliorate the cytokine response. Further randomized clinical trials of combination therapy are needed. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.co-hivandaids.com/ | - |
dc.relation.ispartof | Current Opinion in HIV and AIDS | - |
dc.rights | This is a non-final version of an article published in final form in (provide complete journal citation) | - |
dc.subject | antivirals | - |
dc.subject | coronavirus disease 2019 | - |
dc.subject | severe acute respiratory syndrome coronavirus 2 | - |
dc.subject | treatment | - |
dc.title | Treatment of coronavirus disease 2019 | - |
dc.type | Article | - |
dc.identifier.email | Hung, IFN: ivanhung@hkucc.hku.hk | - |
dc.identifier.authority | Hung, IFN=rp00508 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/COH.0000000000000652 | - |
dc.identifier.pmid | 33002954 | - |
dc.identifier.scopus | eid_2-s2.0-85092514340 | - |
dc.identifier.hkuros | 317183 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 336 | - |
dc.identifier.epage | 340 | - |
dc.identifier.isi | WOS:000587785800003 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1746-630X | - |